p16 gene overexpression in mouse bladder carcinomas

被引:18
作者
Asamoto, M
Hori, T
Baba-Toriyama, H
Sano, M
Takahashi, S
Tsuda, H
Shirai, T
机构
[1] Natl Canc Ctr, Res Inst, Chemotherapy Div, Chuo Ku, Tokyo 104, Japan
[2] Osaka City Univ, Sch Med, Dept Pathol 1, Abeno Ku, Osaka 545, Japan
[3] Nagoya City Univ, Sch Med, Dept Pathol 1, Mizuho Ku, Nagoya, Aichi 467, Japan
关键词
loss of heterozygosity; p16; gene; mouse; bladder carcinoma;
D O I
10.1016/S0304-3835(97)00447-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Deletion of 9p21 has frequently been observed in human bladder carcinomas. A candidate target suppressor gene, p16, was recently identified within this deleted region. In this study, we therefore investigated the loss of heterozygosity (LOH) of the p16 gene which is located on mouse chromosome 4, as well as its expression in mouse bladder carcinomas. We also studied the effects of normal cell contamination on LOH analysis using xenografts in CD-1(ICR) nude mice from B6C3F1 bladder carcinomas. We could not detect any LOH at the p16 locus in the mouse primary bladder carcinomas and xenografts. Surprisingly, overexpression of p16 was found in all primary mouse bladder carcinomas. Using microsatellite polymorphisms, a distinction could be made between PCR products derived from B6C3F1 and CD-1(ICR) nude mice. It was thereby confirmed that effects of normal cell contamination on LOH analysis are negligible when only tumor tissue is carefully sampled. The results suggest that abnormalities of p16 expression may be involved in mouse bladder carcinogenesis, but that gene deletion is not involved. (C) 1998 Elsevier Science Ireland Ltd.
引用
收藏
页码:9 / 13
页数:5
相关论文
共 32 条
  • [1] MOLECULAR MECHANISMS OF TPA-MEDIATED INHIBITION OF GAP-JUNCTIONAL INTERCELLULAR COMMUNICATION - EVIDENCE FOR ACTION ON THE ASSEMBLY OR FUNCTION BUT NOT THE EXPRESSION OF CONNEXIN 43 IN RAT-LIVER EPITHELIAL-CELLS
    ASAMOTO, M
    OYAMADA, M
    ELAOUMARI, A
    GROS, D
    YAMASAKI, H
    [J]. MOLECULAR CARCINOGENESIS, 1991, 4 (04) : 322 - 327
  • [2] CYCLIN D1 IS A NUCLEAR-PROTEIN REQUIRED FOR CELL-CYCLE PROGRESSION IN G(1)
    BALDIN, V
    LUKAS, J
    MARCOTE, MJ
    PAGANO, M
    DRAETTA, G
    [J]. GENES & DEVELOPMENT, 1993, 7 (05) : 812 - 821
  • [3] CAIRNS P, 1994, CANCER RES, V54, P1422
  • [4] FREQUENCY OF HOMOZYGOUS DELETION AT P16/CDKN2 IN PRIMARY HUMAN TUMORS
    CAIRNS, P
    POLASCIK, TJ
    EBY, Y
    TOKINO, K
    CALIFANO, J
    MERLO, A
    MAO, L
    HERATH, J
    JENKINS, R
    WESTRA, W
    RUTTER, JL
    BUCKLER, A
    GABRIELSON, E
    TOCKMAN, M
    CHO, KR
    HEDRICK, L
    BOVA, GS
    ISAACS, W
    KOCH, W
    SCHWAB, D
    SIDRANSKY, D
    [J]. NATURE GENETICS, 1995, 11 (02) : 210 - 212
  • [5] GERADTS J, 1995, CANCER RES, V55, P6006
  • [6] GROWTH SUPPRESSION BY P18, A P16(INK4/MTS1)-RELATED AND P14(INK4B/MTS2)-RELATED CDK6 INHIBITOR, CORRELATES WITH WILD-TYPE PRB FUNCTION
    GUAN, KL
    JENKINS, CW
    LI, Y
    NICHOLS, MA
    WU, XY
    OKEEFE, CL
    MATERA, AG
    XIONG, Y
    [J]. GENES & DEVELOPMENT, 1994, 8 (24) : 2939 - 2952
  • [7] HE J, 1994, CANCER RES, V54, P5804
  • [8] HEGI ME, 1994, CANCER RES, V54, P6257
  • [9] HERZOG CR, 1995, ONCOGENE, V11, P1811
  • [10] CYCLINS AND CANCER .2. CYCLIN-D AND CDK INHIBITORS COME OF AGE
    HUNTER, T
    PINES, J
    [J]. CELL, 1994, 79 (04) : 573 - 582